Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II Study
Blood (2021) 138 (Supplement 1): 2349.
Currently there are no citedby results. Try again later.
